DEXCOM INC

Dexcom’s CGM trial proves non‑insulin type‑2 patients gain better control, satisfaction and lower A1C—unlocking new revenue, reimbursement and market growth.

Dexcom’s executive share sale shows market dynamics but won’t change its strong growth, competitive edge, or patient‑centric strategy in CGM technology.

Dexcom’s insider sale and May 2026 market surge show robust governance and steady growth in digital health, highlighting resilience amid rising rates.

DexCom’s latest Form 4 filing shows executive share sales and robust CGM revenue growth, highlighting strong market performance, operational challenges, and a focus on value‑based reimbursement in the diabetes‑care sector.

Dexcom’s latest CGM tech, FDA‑cleared and improving patient adherence, boosts its stock and fuels a disciplined share‑sale strategy for future growth.

Dexcom shares jump after appointing two independent directors and renaming its technology committee, boosting investor confidence in its governance and growth strategy.

Dexcom’s board moves to trust‑based ownership of shares boost governance and investor confidence, aligning with biotech best practices and market dynamics.

Explore Dexcom’s CGM market dominance, G7 rollout, and robust margins—yet learn how pricing pressures and regulatory hurdles could impact long‑term value.

Dexcom’s recent analyst revisions show mixed sentiment: Canaccord sees upside from its product pipeline, while TD Cowen and Barclays warn of market volatility and regulatory hurdles. Investors watch for earnings and product launches to gauge growth …

Dexcom’s rise in continuous glucose monitoring shows how tech, regulation, and pay‑model shifts power remote patient care—and why it outpaces rivals like Abbott.